JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online June 13, 2008
J Nucl Med 2008, doi:10.2967/jnumed.108.051680
© 2008 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.108.051680v1
49/7/1171    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kung, M.-P.
Right arrow Articles by Kung, H. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kung, M.-P.
Right arrow Articles by Kung, H. F.


In Vivo Imaging of {beta}-Cell Mass in Rats Using 18F-FP-(+)-DTBZ: A Potential PET Ligand for Studying Diabetes Mellitus

Mei-Ping Kung 1, Catherine Hou 1, Brian P. Lieberman 1, Shunichi Oya 1, Datta E. Ponde 1, Eric Blankemeyer 1, Daniel Skovronsky 2, Michael R. Kilbourn 3, and Hank F. Kung 4*

1 Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
2 Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania
3 Department of Radiology, University of Michigan, Ann Arbor, Michigan
4 Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania

* To whom correspondence should be addressed. E-mail: kunghf{at}sunmac.spect.upenn.edu.


   Abstract

Recent studies on gene expression of {beta}-cell mass (BCM) in the pancreas showed that vesicular monoamine transporter 2 (VMAT2) is highly expressed in the BCM (mainly in the islets of Langerhans). Imaging pancreatic BCM may provide an important tool for understanding the relationship between loss of insulin-secreting {beta}-cells and onset of diabetes mellitus. In this article, 9-fluoropropyl-(+)-dihydrotetrabenazine (FP-(+)-DTBZ), which is a VMAT2 imaging agent, was evaluated as a PET agent for estimating BCM in vivo. Methods: Organ biodistribution after an intravenous injection of 18F-FP-(+)-DTBZ (active isomer) and 18F-FP-(-)-DTBZ (inactive isomer) was evaluated in normal rats. The specificity of uptake of 18F-FP-(+)-DTBZ was assessed by a pretreatment (3.8 mg of (+)-DTBZ per kilogram and 3.5 mg of FP-(+)-DTBZ per kilogram, intravenously, 5 min prior) or coadministration (2 mg of (+)-DTBZ per kilogram). PET studies were performed in normal rats. Results: The in vivo biodistribution of 18F-FP-(+)-DTBZ in rats showed the highest uptake in the pancreas (5% dose/g at 30 min after injection), whereas 18F-FP-(-)-DTBZ showed a very low pancreas uptake. Rats pretreated with FP-(+)-DTBZ displayed a 78% blockade of pancreas uptake. PET studies in normal rats demonstrated an avid pancreas uptake of 18F-FP-(+)-DTBZ. Conclusion: The preliminary data obtained with 18F-FP-(+)-DTBZ suggest that this fluorinated derivative of DTBZ shows good pancreas specificity and has the potential to be useful for quantitative measurement of VMAT2 binding sites reflecting BCM in the pancreas.

Key Words: diabetes, beta-cell mass, pancreas imaging, VMAT2







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.